Compounded tirzepatide unboxings: what TikTok glosses over

What did @emilyglp1 actually say?

She unboxed a vial she called "compound intersapatide" (tirzepatide) with niacinamide from Empower Pharmacy, showed the cold-chain packaging, syringes, and alcohol wipes, and mentioned she is moving up to a 7.5 mg dose. She also noted her previous shipment came from Red Rock Pharmacy. No dramatic health claims, no cure promises. Just an unboxing. That matters, because it sets realistic expectations about what ordering compounded tirzepatide actually looks like in practice.

The video is almost entirely observational. She describes what is in the box, reads the label aloud, and asks the comment section for tips on tolerating a dose increase. The closest thing to a medical claim is that the label tells her "how many units to inject" and "the dose," which is accurate for how compounded peptide vials are labeled in unit-based dosing.

Does the science back this up?

The core product here, compounded tirzepatide, sits in a genuinely complicated regulatory space. The underlying molecule has strong clinical support. But compounded versions are not FDA-approved, and the evidence base for their specific formulations is essentially zero.

Tirzepatide itself has serious clinical backing. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 22.5% mean body weight reduction over 72 weeks in adults with obesity. That is for brand-name Zepbound at specific doses in a controlled setting. Compounded tirzepatide with niacinamide added is a different formulation. No published randomized controlled trials exist for this specific compound. The niacinamide addition, which some compounding pharmacies include as a stability aid, has not been studied in combination with tirzepatide in humans in any peer-reviewed trial this writer can find. That is not proof it is harmful, but it is also not proof it is equivalent or safe at scale.

What did they get wrong (or right)?

She got the packaging reality right. Empower Pharmacy is one of the larger 503B outsourcing facilities in the US, and their cold-chain shipping with ice packs is consistent with what proper peptide handling requires. Tirzepatide degrades at room temperature, so that foam block matters more than it looks.

The mispronunciation of tirzepatide as "intersapatide" and then "zapatide" is minor and not a safety issue, but worth noting because it signals she may be navigating this without a lot of clinical guidance, which is common in compounded GLP-1 patients.

The niacinamide additive deserves more scrutiny than she gives it. She reads it off the label without comment, but patients should know this is not a standard component of FDA-approved tirzepatide. The FDA specifically warned in October 2024 that compounded tirzepatide is not the same as Zepbound or Mounjaro, and that added ingredients like niacinamide have not been evaluated for safety or efficacy in this combination.

Her dose escalation from 5 mg to 7.5 mg is not something this fact-check will weigh in on clinically. What is worth saying: that escalation decision should be made with a prescriber, not crowdsourced from TikTok comments.

What should you actually know?

Compounded tirzepatide became widely available because Zepbound and Mounjaro were on the FDA drug shortage list. In March 2025, the FDA declared the shortage resolved, which means compounding pharmacies are now operating in much murkier legal territory. The agency has signaled enforcement action against pharmacies continuing to compound tirzepatide outside of specific exemptions.

This does not mean every Empower Pharmacy patient will suddenly lose access, but it does mean the regulatory ground is shifting fast. If you are on compounded tirzepatide, your prescriber should be tracking this, because supply continuity is a real question right now.

The quality control gap is also real. A 2023 analysis by Valisure flagged significant potency variability in compounded semaglutide products. No equivalent public analysis of compounded tirzepatide potency exists yet, but the same manufacturing variability risks apply. Getting your medication from a 503B facility like Empower carries fewer risks than a 503A compounding pharmacy, but it is still not the same oversight structure as an FDA-approved drug.

Bottom line: the unboxing video is harmless as content goes. The product it features carries real uncertainties that a 37,000-view TikTok audience deserves to understand.